Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01690143 · OUTCOME

Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple Myeloma(MM) [Phase I Portion of Study]

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation · Source last updated 2018-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/m2
Interval / dispersion
Not reported
Time frame
Up to 4 1/2 months

What was measured

The maximum tolerated dose of carfilzomib that can be safely combined with high dose melphalan as conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma meeting eligibility criteria.

Analysis population: Patients who underwent transplantation during phase 1

Groups in this outcome

Patients Undergoing Transplantation

All patients who receive transplant in the phase 1 of the study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Patients Undergoing Transplantation15

Reported measurements

Source class 1
Values in mg/m2 · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Patients Undergoing Transplantation56Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        56
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
The maximum tolerated dose of carfilzomib that can be safely combined with high dose melphalan as conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma meeting eligibility criteria.
groups
  1. description
    All patients who receive transplant in the phase 1 of the study
    id
    OG000
    title
    Patients Undergoing Transplantation
param Type
NUMBER
population Description
Patients who underwent transplantation during phase 1
reporting Status
POSTED
time Frame
Up to 4 1/2 months
title
Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple Myeloma(MM) [Phase I Portion of Study]
type
PRIMARY
unit Of Measure
mg/m2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice